SLC5A2 and hydrops fetalis: Randomized clinical trials (RCTs) of SGLT-2 inhibitors, such as empagliflozin, canagliflozin, and dapagliflozin, have shown that these drugs not only lower plasma glucose concentration, but also have CV benefits [4,5,6] and reduce the risk of HF [7,8].